Devonian Announces the Filing of a New Patent Application Relating to the Use of Thykamine as an Antifibrotic Agent

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, announces the filing of a new patent application directed to the use of Thykamine as an antifibrotic agent.

Backed by in vivo data, the patent application displays the potential effectiveness of thylakoid extracts in treating and slowing the progression of fibrosis, and in down regulating several genes associated with fibrogenesis in several organs and tissues.

“The filing is timely as it supports the potential use of Thykamine in treating fibrotic diseases expanding therefore its therapeutic applications. This new patent application is another pivotal component of our broad strategy of expanding our list of patents.” said Dr. André P. Boulet, Chief Scientific Officer of the Company.

About Fibrosis^1,2,3

Fibrosis is a complicated physiological process that includes both acute and long-term inflammatory conditions. It is distinguished by an overabundance of fibrous connective tissue accumulating in and around injured or inflammatory tissues, leading to the formation of long-lasting scars. Fibrosis is the last stage of chronic disease in a number of organs, including the skin, heart, lungs, gut, liver, and kidneys. Increased morbidity and mortality result from the loss of structural integrity and function caused by fibrotic tissue pathologic accumulation.

About Thykamine

Thykamine, the first pharmaceutical product issued from Devonian’s SUPREX platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a large Phase II study in adult patients with mild-to-moderate Atopic Dermatitis. Both Thykamine and SUPREX platform are covered by patents issued in several North American, European and Asian countries.